Search Results
You are looking at 1 - 10 of 10 items for
- Author: Arthur S Tischler x
- Refine by access: All content x
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Department of Pathology and Laboratory Medicine, Department of Pathology, Department of Pathology, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Box 802, Boston, Massachusetts 02111, USA
Search for other papers by Ronald R deKrijger in
Google Scholar
PubMed
Pathologists using their routine diagnostic tools can contribute both to the care of patients with pheochromocytoma/paraganglioma and to understanding the pathobiology of the tumors. They can document details of tissue organization and cytology that are accessible only by microscopy and can characterize admixtures of cell types that are morphologically distinct or show differential expression of immunohistochemical markers. Current roles and challenges for pathologists include differential diagnosis, identifying clues to the presence of hereditary disease, and effective communication of pathology information for clinical and research purposes. Future roles will increasingly involve risk stratification, identification of actionable targets for personalized therapies, and aiding the interpretation of molecular tests by helping characterize genetic variants of unknown significance. It remains to be determined to what extent the need for pathology input will be overshadowed by the availability of genetic testing and other molecular analyses at ever-decreasing cost, together with very effective clinical paradigms for risk stratification and patient care.
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by Judith Favier in
Google Scholar
PubMed
Experimental models for pheochromocytoma and paraganglioma are needed for basic pathobiology research and for preclinical testing of drugs to improve treatment of patients with these tumors, especially patients with metastatic disease. The paucity of models reflects the rarity of the tumors, their slow growth, and their genetic complexity. While there are no human cell line or xenograft models that faithfully recapitulate the genotype or phenotype of these tumors, the past decade has shown progress in development and utilization of animal models, including a mouse and a rat model for SDH-deficient pheochromocytoma associated with germline Sdhb mutations. There are also innovative approaches to preclinical testing of potential treatments in primary cultures of human tumors. Challenges with these primary cultures include how to account for heterogeneous cell populations that will vary depending on the initial tumor dissociation and how to distinguish drug effects on neoplastic vs normal cells. The feasible duration for maintaining cultures must also be balanced against time required to reliably assess drug efficacy. Considerations potentially important for all in vitro studies include species differences, phenotype drift, changes that occur in the transition from tissue to cell culture, and the O2 concentration in which cultures are maintained.
Search for other papers by James F Powers in
Google Scholar
PubMed
Search for other papers by Brent Cochran in
Google Scholar
PubMed
Search for other papers by James D Baleja in
Google Scholar
PubMed
Search for other papers by Hadley D Sikes in
Google Scholar
PubMed
Search for other papers by Xue Zhang in
Google Scholar
PubMed
Search for other papers by Inna Lomakin in
Google Scholar
PubMed
Search for other papers by Troy Langford in
Google Scholar
PubMed
Search for other papers by Kassi Taylor Stein in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
We describe a unique patient-derived xenograft (PDX) and cell culture model of succinate dehydrogenase-deficient gastrointestinal stromal tumor (SDH-deficient GIST), a rare mesenchymal tumor that can occur in association with paragangliomas in hereditary and non-hereditary syndromes. This model is potentially important for what it might reveal specifically pertinent to this rare tumor type and, more broadly, to other types of SDH-deficient tumors. The primary tumor and xenografts show a very high proliferative fraction, and distinctive morphology characterized by tiny cells with marked autophagic activity. It is likely that these characteristics resulted from the combination of the germline SDHB mutation and a somatic KRAS G12D mutation. The most broadly relevant findings to date concern oxygen and oxidative stress. In paragangliomas harboring SDHx mutations, both hypoxic signaling and oxidative stress are putative drivers of tumor growth. However, there are no models for SDH-deficient paragangliomas. This related model is the first from a SDHB-mutated human tumor that can be experimentally manipulated to study mechanisms of oxygen effects and novel treatment strategies. Our data suggest that tumor growth and survival require a balance between protective effects of hypoxic signaling vs deleterious effects of oxidative stress. While reduced oxygen concentration promotes tumor cell survival, a further survival benefit is achieved with antioxidants. This suggests potential use of drugs that increase oxidative stress as novel therapies. In addition, autophagy, which has not been reported as a major finding in any type of SDH-deficient tumor, is a potential target of agents that might trigger autophagic cell death.
Search for other papers by Elizabeth G Grubbs in
Google Scholar
PubMed
Search for other papers by Ronald M Lechan in
Google Scholar
PubMed
Search for other papers by Beth Edeiken-Monroe in
Google Scholar
PubMed
Search for other papers by Gilbert J Cote in
Google Scholar
PubMed
Search for other papers by Chardria Trotter in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by Robert F Gagel in
Google Scholar
PubMed
Forty years ago, physicians caring for the J-kindred, a 100+ member family with multiple endocrine neoplasia type 2A (MEN2A), hypothesized that early thyroidectomy based on measurement of the biomarker calcitonin could cure patients at risk for development of medullary thyroid carcinoma (MTC). We re-evaluated 22 family members with proven RET proto-oncogene mutations (C634G) who underwent thyroidectomy and central lymphadenectomy between 1972 and 1994 based on stimulated calcitonin abnormalities. Current disease status was evaluated by serum calcitonin measurement and neck ultrasound in 18 of the 22 prospectively screened patients. The median age of the cohort at thyroidectomy was 16.5 years (range 9–24). The median duration of follow-up at the time of examination was 40 years (range 21–43) with a median current age of 52 years (range 34–65). Fifteen of the 18 patients had no detectable serum calcitonin (<2 pg/mL). Three had detectable serum calcitonin measurements, inappropriately elevated following total thyroidectomy. None of the 16 patients imaged had an abnormal ultrasound. Survival analysis shows no MTC-related deaths in the prospectively screened patients, whereas there were many in prior generations. Early thyroidectomy based on biomarker testing has rendered 15 of 18 MEN2A patients (83%) calcitonin-free with a median follow-up period of 40 years. There have been no deaths in the prospectively screened and thyroidectomized group. We conclude that early thyroidectomy and central lymph node dissection is an effective prophylactic treatment for hereditary MTC.
Section on Medical Neuroendocrinology, Clinical Neuroendocrinology Branch, Laboratory of Pathology, Intramural Science PRGMS, Laboratory of Diagnostic Radiology, Metabolism Branch, Institute of Experimental Endocrinology, Department of Pathology, Nuclear Medicine Department, Medical Oncology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 1E-3140, 10 Center Drive MSC-1109, Bethesda, Maryland 20892-1109, USA
Search for other papers by Lucia Martiniova in
Google Scholar
PubMed
Search for other papers by Shiromi M Perera in
Google Scholar
PubMed
Search for other papers by Frederieke M Brouwers in
Google Scholar
PubMed
Search for other papers by Salvatore Alesci in
Google Scholar
PubMed
Search for other papers by Mones Abu-Asab in
Google Scholar
PubMed
Search for other papers by Amanda F Marvelle in
Google Scholar
PubMed
Search for other papers by Dale O Kiesewetter in
Google Scholar
PubMed
Search for other papers by David Thomasson in
Google Scholar
PubMed
Search for other papers by John C Morris in
Google Scholar
PubMed
Search for other papers by Richard Kvetnansky in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by James C Reynolds in
Google Scholar
PubMed
Search for other papers by Antonio Tito Fojo in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
[131I]meta-iodobenzylguanidine ([131I]MIBG) is the most commonly used treatment for metastatic pheochromocytoma and paraganglioma. It enters the chromaffin cells via the membrane norepinephrine transporter; however, its success has been modest. We studied the ability of histone deacetylase (HDAC) inhibitors to enhance [123I]MIBG uptake by tumors in a mouse metastatic pheochromocytoma model. HDAC inhibitors are known to arrest growth, induce differentiation and apoptosis in various cancer cells, and further inhibit tumor growth. We report the in vitro and in vivo effects of two HDAC inhibitors, romidepsin and trichostatin A, on the uptake of [3H]norepinephrine, [123I]MIBG, and [18F]fluorodopamine in a mouse model of metastatic pheochromocytoma. The effects of both inhibitors on norepinephrine transporter activity were assessed in mouse pheochromocytoma (MPC) cells by using the transporter-blocking agent desipramine and the vesicular-blocking agent reserpine. HDAC inhibitors increased [3H]norepinephrine, [123I]MIBG, and [18F]fluorodopamine uptake through the norepinephrine transporter in MPC cells. In vivo, inhibitor treatment resulted in significantly increased uptake of [18F]fluorodopamine positron emission tomography (PET) in pheochromocytoma liver metastases (19.1±3.2% injected dose per gram of tumor (%ID/g) compared to liver metastases in pretreatment scans 5.9±0.6%; P<0.001). Biodistribution analysis after inhibitors treatment confirmed the PET results. The uptake of [123I]MIBG was significantly increased in liver metastases 9.5±1.1% compared to 3.19±0.4% in untreated control liver metastases (P<0.05). We found that HDAC inhibitors caused an increase in the amount of norepinephrine transporter expressed in tumors. HDAC inhibitors may enhance the therapeutic efficacy of [131I]MIBG treatment in patients with advanced malignant pheochromocytoma and paraganglioma.
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Search for other papers by Stefan R Bornstein in
Google Scholar
PubMed
Search for other papers by Frederieke M Brouwers in
Google Scholar
PubMed
Search for other papers by Nai-Kong V Cheung in
Google Scholar
PubMed
Search for other papers by Patricia L Dahia in
Google Scholar
PubMed
Search for other papers by Ronald R de Krijger in
Google Scholar
PubMed
Search for other papers by Thomas J Giordano in
Google Scholar
PubMed
Search for other papers by Lloyd A Greene in
Google Scholar
PubMed
Search for other papers by David S Goldstein in
Google Scholar
PubMed
Search for other papers by Hendrik Lehnert in
Google Scholar
PubMed
Search for other papers by William M Manger in
Google Scholar
PubMed
Search for other papers by John M Maris in
Google Scholar
PubMed
Search for other papers by Hartmut P H Neumann in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Barry L Shulkin in
Google Scholar
PubMed
Search for other papers by David I Smith in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by William F Young Jr in
Google Scholar
PubMed
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th–18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.
Search for other papers by James F Powers in
Google Scholar
PubMed
Search for other papers by Brent Cochran in
Google Scholar
PubMed
Search for other papers by James D Baleja in
Google Scholar
PubMed
Search for other papers by Hadley D Sikes in
Google Scholar
PubMed
Search for other papers by Andrew D Pattison in
Google Scholar
PubMed
Search for other papers by Xue Zhang in
Google Scholar
PubMed
Search for other papers by Inna Lomakin in
Google Scholar
PubMed
Search for other papers by Annette Shepard-Barry in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Sun Jin Moon in
Google Scholar
PubMed
Search for other papers by Troy F Langford in
Google Scholar
PubMed
Search for other papers by Kassi Taylor Stein in
Google Scholar
PubMed
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Search for other papers by Richard W Tothill in
Google Scholar
PubMed
Search for other papers by Yingbin Ouyang in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Tumors caused by loss-of-function mutations in genes encoding TCA cycle enzymes have been recently discovered and are now of great interest. Mutations in succinate dehydrogenase (SDH) subunits cause pheochromocytoma/paraganglioma (PCPG) and syndromically associated tumors, which differ phenotypically and clinically from more common SDH-intact tumors of the same types. Consequences of SDH deficiency include rewired metabolism, pseudohypoxic signaling and altered redox balance. PCPG with SDHB mutations are particularly aggressive, and development of treatments has been hampered by lack of valid experimental models. Attempts to develop mouse models have been unsuccessful. Using a new strategy, we developed a xenograft and cell line model of SDH-deficient pheochromocytoma from rats with a heterozygous germline Sdhb mutation. The genome, transcriptome and metabolome of this model, called RS0, closely resemble those of SDHB-mutated human PCPGs, making it the most valid model now available. Strategies employed to develop RS0 may be broadly applicable to other SDH-deficient tumors.
Search for other papers by James F Powers in
Google Scholar
PubMed
Search for other papers by Brent Cochran in
Google Scholar
PubMed
Search for other papers by James D Baleja in
Google Scholar
PubMed
Search for other papers by Hadley D Sikes in
Google Scholar
PubMed
Search for other papers by Andrew D Pattison in
Google Scholar
PubMed
Search for other papers by Xue Zhang in
Google Scholar
PubMed
Search for other papers by Inna Lomakin in
Google Scholar
PubMed
Search for other papers by Annette Shepard-Barry in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Sun Jin Moon in
Google Scholar
PubMed
Search for other papers by Troy F Langford in
Google Scholar
PubMed
Search for other papers by Kassi Taylor Stein in
Google Scholar
PubMed
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Search for other papers by Richard W Tothill in
Google Scholar
PubMed
Search for other papers by Yingbin Ouyang in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by Roland Därr in
Google Scholar
PubMed
Search for other papers by Joan Nambuba in
Google Scholar
PubMed
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Ingo Janssen in
Google Scholar
PubMed
Search for other papers by Maria Merino in
Google Scholar
PubMed
Search for other papers by Milena Todorovic in
Google Scholar
PubMed
Search for other papers by Bela Balint in
Google Scholar
PubMed
1st Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovakia
Search for other papers by Ivana Jochmanova in
Google Scholar
PubMed
Search for other papers by Josef T Prchal in
Google Scholar
PubMed
Search for other papers by Ronald M Lechan in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by Vera Popovic in
Google Scholar
PubMed
Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Search for other papers by Karen T Adams in
Google Scholar
PubMed
Search for other papers by F Ryan Prall in
Google Scholar
PubMed
Search for other papers by Alexander Ling in
Google Scholar
PubMed
Search for other papers by Meredith R Golomb in
Google Scholar
PubMed
Search for other papers by Michael Ferguson in
Google Scholar
PubMed
Search for other papers by Naris Nilubol in
Google Scholar
PubMed
Search for other papers by Clara C Chen in
Google Scholar
PubMed
Search for other papers by Emily Chew in
Google Scholar
PubMed
Search for other papers by David Taïeb in
Google Scholar
PubMed
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
Search for other papers by Tito Fojo in
Google Scholar
PubMed
Search for other papers by Chunzhang Yang in
Google Scholar
PubMed
Search for other papers by Electron Kebebew in
Google Scholar
PubMed
Search for other papers by Zhengping Zhuang in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11–46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8–38) and SOMs at 29 years (range 22–38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29% of all cases, and SOMs in 40, 40 and 60%, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57%), previously thought to be pathognomonic for von Hippel–Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [18F]-fluorodihydroxyphenylalanine ([18F]-FDOPA). Therefore, [18F]-FDOPA PET/CT, not [68Ga]-(DOTA)-[Tyr3]-octreotate ([68Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The long-term prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.
Search for other papers by Hartmut P Neumann in
Google Scholar
PubMed
Search for other papers by William F Young Jr in
Google Scholar
PubMed
Search for other papers by Tobias Krauss in
Google Scholar
PubMed
Search for other papers by Jean-Pierre Bayley in
Google Scholar
PubMed
Search for other papers by Francesca Schiavi in
Google Scholar
PubMed
Search for other papers by Giuseppe Opocher in
Google Scholar
PubMed
Search for other papers by Carsten C Boedeker in
Google Scholar
PubMed
Search for other papers by Amit Tirosh in
Google Scholar
PubMed
Assistance Publique – Hôpitaux de Marseille (AP-HM), Hôpital de la Conception, Centre de Référence des Maladies Rares Hypophysaires HYPO, Marseille, France
Search for other papers by Frederic Castinetti in
Google Scholar
PubMed
Search for other papers by Juri Ruf in
Google Scholar
PubMed
Search for other papers by Dmitry Beltsevich in
Google Scholar
PubMed
Search for other papers by Martin Walz in
Google Scholar
PubMed
Search for other papers by Harald-Thomas Groeben in
Google Scholar
PubMed
Search for other papers by Ernst von Dobschuetz in
Google Scholar
PubMed
Department of Surgery, Region Östergötland, Linköping, Sweden
Search for other papers by Oliver Gimm in
Google Scholar
PubMed
Search for other papers by Nelson Wohllk in
Google Scholar
PubMed
Search for other papers by Marija Pfeifer in
Google Scholar
PubMed
Search for other papers by Delmar M Lourenço Jr in
Google Scholar
PubMed
Search for other papers by Mariola Peczkowska in
Google Scholar
PubMed
Search for other papers by Attila Patocs in
Google Scholar
PubMed
Search for other papers by Joanne Ngeow in
Google Scholar
PubMed
Search for other papers by Özer Makay in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Arthur Tischler in
Google Scholar
PubMed
Search for other papers by Helena Leijon in
Google Scholar
PubMed
Search for other papers by Gianmaria Pennelli in
Google Scholar
PubMed
Search for other papers by Karina Villar Gómez de las Heras in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Birke Bausch in
Google Scholar
PubMed
Search for other papers by Charis Eng in
Google Scholar
PubMed
Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10% of all cases has been overturned, with >35% of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.
